List of Next-Gen Sequencing Companies in United States - 183

Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Santé Luxembourg. ABL acquired all the patents and IP rights from TherapyEdge, Inc. in 2005 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management products, including TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, HepatiC™ and the DPM which are used for data and patient management, monitoring and personalized reporting applications. COVID-19: CE mark (07/2020)

Abterra Biosciences is reimagining antibody discovery and sequencing by harnessing the latest next-generation sequencing, mass spec, machine learning. Abterra Biosciences is enabling the next-generation of antibody therapeutics. Our technologies use the latest in next-generation sequencing.

Accel Diagnostics is medical diagnostic company developing proprietary point-of-care diagnostic assay for the diagnosis, monitoring and management of a wide variety of medical conditions. We are dedicated to making a difference in the quality of life of millions of patients through technology and innovation. AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests anytime and anywhere. The Company's patented platform technology transforms the patient blood testing paradigm, from lab-centered to near-patient. The technology bringing significant advantages in terms of simplicity, time to result, care delivery, and cost over current standard lab-based diagnostics. During COVID-19 pademic Accel Diagnostics began to operate the ADX Diagnostic Lab to provide high quality COVID testing in Houston, TX.

AccuGenomics is a biotechnology company that specializes in a unique spike-in control technology to enhance the accuracy of clinical sequencing tests for low abundance biomarkers and infectious pathogens.

AcelaBio, wholly owned by The Alimentiv Health Trust, was incorporated in 2020 and aims to meet the growing clinical research demand for quality and efficiency in laboratory service. Our state-of-the-art facility, located in San Diego, California, is built on deep expertise in clinical and precision medicine research and our scientific and operational experts are dedicated to delivering reliable, high-quality data.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has a translational collaboration with AstraZeneca to investigate the use of immunoSEQ T-MAP. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.

Advanced Cellular Dynamics (ACD) is a world-leader in the production, provision and application of novel cell-based assay systems. Our capabilities provide us with a unique capability to explore a variety of biological entities and systems. We have deep-rooted expertise in kinases, GPCRs, ion channels and transcription factors - to name a few. Those skills are applied to a variety of experimental systems that include (but aren't limited to) oncology, immunology and neurobiology. We also leverage these skills to provide our global clientele with contract research services. Whether you want to disrupt a specific gene in stem cells, or create a new biological cell-based assay in your tissue/cell line of choice, we have the knowledge and skills to help you succeed!

Aegea Biotechnologies, Inc. is a technology company that is developing a series of reagents, research kits and in-vitro diagnostic (IVD) products for molecular analysis based on novel, patented and proprietary nucleic acid chemistries and methodologies.

The Genomics Core serves the Einstein scientific community by providing a broad range of services, utilizing current and emerging nucleic acid technologies. Single-cell assays, MPS, Microarrays, real-time PCR, Sanger sequencing and assay automation are available. The Core provides a number of technologies for genotyping DNA from humans or model organisms, varying from SNP (single nucleotide polymorphism) typing to targeted sequencing for variant discovery.

Alida Biosciences is an early-stage, VC backed startup in San Diego focused on developing novel genomic analysis tools. The company’s technology will advance the understanding of RNA biology and provide actionable information for improving human health.

Allele Diagnostics, Inc., located in Spokane, WA, was established in 2014 to offer superior genetic testing services. We feel that high-quality testing, reporting, and services can be offered to you with quick results. We pride ourselves in being a laboratory that offers the genetic counseling services clinicians need in a genetic testing company. We combine this service with reliable, fast, accurate test results provided to you via user-friendly and conveniently accessible reports. At Allele Diagnostics, we are passionate about providing reliable answers as quickly and accurately as possible. We continuously strive to improve the efficiency of our workflow and improve the quality of our test results. We encourage feedback from our clients on how we can improve or assist in bringing your ideas into a clinical testing environment. Utilizing our extensive experience in genetic testing, we can work with you to develop solutions to the challenges you have previously experienced in receiving fast, accurate results. Additionally, we are always looking for new and better ways to provide answers to genetic questions and are continuously evaluating novel technologies to see how they can fit into our laboratory given the rapidly evolving clinical genetic testing space. Allele Diagnostics is a CLIA and CAP certified clinical laboratory committed to providing superior testing services for the best patient care possible. We are currently licensed in California, Florida, and Pennsylvania and are pursuing various other state specific licenses.

AlphaDERA Labs, LLC. is a full-service medical laboratory providing wellness testing, routine blood chemistry, prescription & illicit drug test including urinary tract testing, respiratory pathogen testing, and COV-19 antigen testing for healthcare facilities, clinics, and PCR Covid-19 testing for patients.

Amplicon independently validates all COVID19 IgM/IG Rapid Tests offered. In business since 1996, Amplicon proactively performs investigational research to confirm the claims of all manufacturers. Doing our due diligence is a critical part of bringing the best performing tests to Medical Professionals. To learn more, please visit https://covid19.ampliconexpress.com/

AptaMatrix is a privately held, start-up biotechnology company headquartered in Syracuse, New York. The company's focus is to accelerate the rate of aptamer discovery using its patent pending High Throughput Screening of Aptamers (HTSA) approach in addition to developing its novel AlloSwitch™ sensor technology capable of a) creating rapid diagnostic tools for detection of chemical and biological targets, and b) leveraging this diagnostic platform for drug discovery applications. AlloSwitches™, have demonstrated the ability to transduce molecular recognition of biological targets into a real-time (seconds) optical signal for identifying environmental and terrorist released contaminants in liquid systems. HTSA and AlloSwitch solutions are built on patented biotechnology based on years of leading-edge biological research and industry partnerships at Syracuse University. The HTSA approach leverages the high throughput capabilities of deep-sequencing technology. All sequencing activity is managed by our Genomics Division and conducted on our Illumina GAIIx platforms. Data analysis is supported by our in-house bioinformatics team. In addition to supporting internal research and development, our genomics division actively supports both academic and commercial deep-sequencing projects.

Apton is a California-based biotechnology company that manufactures and supplies single-molecule detection and sequencing imaging systems for clinical applications.

Arbor Bio is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines, with the most extensive toolbox of proprietary genomic editors in the industry. We have the unique ability to work backward from disease pathology and choose the optimal editors or combination of editors for the disease in question.

ArcherDX is developing and seeking regulatory clearances for next-generation sequencing (NGS) diagnostics to help solve for the underutilization of targeted cancer therapies.

ARL Bio Pharma is a contract laboratory that provides analytical and microbiological testing for the pharmaceutical industry. Since 1998, ARL has supported the industry-wide commitment to deliver high-quality drug products by providing guidance and test services for all phases of the product lifecycle following USP, FDA, and ICH guidelines. Whether you are a raw material supplier, equipment manufacturer, pharmaceutical manufacturer, pharmacy, or health-system we provide the testing needed to get your drug products ready for release. ARL's dedicated team oversees the entire process from understanding your goals to providing results and helping interpret the data. ARL Bio Pharma is an FDA registered and audited analytical laboratory and DEA licensed for Schedules I through V. The laboratory is ISO 17025:2017 accredited as applicable to our scope of accreditation. 17025:2017 accreditation independently demonstrates ARL's ability to not only comply with quality requirements, but to competently perform specified tests and activities.

Avance Biosciences is a leading CRO providing GLP & GMP-compliant assay development, assay validation, and sample testing services to support biological drug development and manufacturing activities world-wide. We provide customized solutions for cell and gene therapies testing including: ID testing by Sanger and NGS sequencing , next-gen sequencing on/off target assays, preclinical DNA & RNA biodistribution studies, mRNA Drug Product, Drug Substance and raw material testing including ID and...

Axbio is a semiconductor-biotechnology company, developing cutting-edge technologies including nanopore sequencing, Bio-CMOS chips, and electrochemical sensors. Its sequencing and molecular diagnostics products are suitable for academia and industry users, serving large research laboratories as well as small clinics.

Basepair is a next generation bioinformatics company. Through a combination of intuitive interfaces and modern architecture we are reimagining what a commercial platform can deliver to R&D organizations. We're on a mission to make genomic data analysis & visualization more accessible to a broader range of scientists so that the promise of precision medicine can become a reality. One of the biggest challenges preventing this now arguably lies not with how the data gets generated and processed, but who is able to perform the analysis and understand what the resulting data means. Limiting this work to a select few, whether through choice or more often because of technology restrictions, especially for routine analyses, leads to reduced efficiency in R&D teams, longer times to market for assay manufacturers and increased turnaround times in clinical settings. Unlike other more traditional alternatives, our philosophy is not to ask bioinformaticians to change the way they work by having to build workflows on our platform. Instead, once they are built and ready for sharing or production settings, Basepair can significantly improve and accelerate both scaling & deployment to colleagues, collaborators and customers wherever they happen to be in the world. To do this in a way that is adapted to the dynamics of the market today, we believe a bioinformatics platform needs to: 1) Leverage the compute and storage resources in a third party cloud account without the requirement of installing inside an organization's vpc 2) Facilitate the bundling of analysis with the sale of a kit or assay through easy white labeling and tokens/coupons 3) Support ever increasing sample volumes and application areas through an extensible architecture that scales to millions of records, enables complete sample provenance and reduces cloud costs Introducing Basepair…bioinformatics reinvented.

BioDiscovery, Inc. is dedicated to the development of state-of-the-art software products for life science research as well as clinical applications. Our mission is to enable scientists to eliminate disease and suffering through novel application of computational technologies and translating these findings directly and rapidly to clinical use. From its inception in 1997, BioDiscovery has been an innovative leader in the microarray informatics field having introduced the first dedicated commercial software tool for analyzing microarray images. Since then, innovation has continued to be a top priority. Our employees are excited about solving difficult problems and enabling scientist to make significant scientific breakthroughs. Our passion to make a difference has further extended the company’s reach into creating the most comprehensive enterprise-wide system for clinical applications enabling research findings to make direct impact on patient care. BioDiscovery is an equal opportunity employer with great benefits and a friendly, high-energy atmosphere. The company is headquartered in sunny Southern California near the Los Angeles International Airport (LAX) and has European headquarters in Cambridge, UK. We are always looking for talented individuals, eager to make a real difference, to join our company.

Biofidelity is a rapidly growing commercial-stage genomic technology company dedicated to bringing the benefits of precision medicine to patients around the world. We have launched our first product, ASPYRE-Lung, in the US and we have an extensive pipeline of novel products. Biofidelity has developed a novel molecular biology technology which enables genomic analysis for cancer diagnosis to be carried out locally, quickly and far more cost-effectively.

Formerly called Bioline, now acquired by Meridian Bioscience, as part of Meridian Life Science business unit, was founded in 1992 and based in London, UK. Meridian Bioscience is a fully integrated company with two business units dedicated to diagnostics and life science. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Meridian Life Science unit,with large-scale manufacturing capabilities and over 3500 products, provides the most comprehensive portfolio of raw materials for the clinical development of any immunological or molecular test. Our molecular reagents are used by biologists and other research scientists to perform test-assays and research in many fields from medical, biotechnology and marine biology to food and agriculture technology as well as forensic and environmental sciences, where life scientists have come to depend upon the outstanding quality and reliability of our reagents. We have developed and manufactured a portfolio of more than 300 reagents and kits, many of them proprietary, for molecular biology, cell analysis and nucleic acid and protein separation and purification. Meridian operates under an ISO 13485 quality system and is one of the world's few manufacturers of ultra-pure dNTPs, as well as a variety of enzymes and biochemicals.

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. We offer OGM solutions for applications across basic, translational and clinical research. Bionano also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through our Bionano Laboratories business, wey also offer OGM-based diagnostic testing services.

Biostate.AI is a startup founded in 2023 with the mission of developing generative AI for predictive omics analytics in the healthcare sector. They offer services such as RNA sequencing, DNA sequencing, image sequencing, image data analysis, and more. The company aims to lower costs and increase the utility of RNA sequencing for research and drug discovery.

We believe a world yearning for hope and joy needs the graduates of Brigham Young University—disciples of Jesus Christ who are driven by love for God and His children and who are prepared to serve and lead. This preparation demands a unique university model: at BYU, belief enhances inquiry, study amplifies faith, and revelation leads to rich understanding; at BYU, helping students develop their full divine potential is central to both our teaching and our scholarship. As the flagship higher education institution of The Church of Jesus Christ of Latter-day Saints, BYU strives to be among the exceptional universities in the world and an essential university for the world.

Bullseye Biosciences is a therapeutics discovery company revolutionizing drug development through robotics and evolution. Our platform operationalizes cutting-edge directed evolution technology by incorporating automation and Next Generation Sequencing. By targeting challenging drivers of human disease, we are creating life-saving medicines for cardiometabolic, inflammation, and oncology patients with the highest needs.

Cambridge Technologies is an independent owner-operated custom vaccine company working with veterinarians and livestock producers to provide solutions to animal health problems. We use cutting-edge molecular diagnostic and manufacturing techniques to manage the entire custom vaccine process and to provide you with the best possible solutions for managing emerging health problems. Diagnostic and research scientists work in a modern laboratory specializing in personalized service. Techniques including metagenomics, genetic sequencing, qPCR, culture, sensitivity and serology will be employed as needed to precisely determine the right isolates needed for vaccine production. Research scientists alongside the diagnosticians keep Cambridge on the cutting-edge of isolate identification and characterization. Cambridge Technologies vaccines are formulated and produced at our USDA-licensed 37,000-square-foot manufacturing facility featuring a state-of-the-art fermentation suite. The vaccine production team has extensive experience in diagnostics, R&D, quality control, regulatory affairs, and both commercial and custom vaccine production. Vaccines from Cambridge Technologies are truly customized to the customer’s needs, including a range of adjuvant choices, label options, and SoliDose implant delivery in bovine products.

Cantata Bio is enabling researchers and clinicians to solve tomorrow’s most challenging scientific problems through novel, multiomic approaches that unlock access to genomic and metagenomic information at unprecedented levels. Combining propriety technologies with platform solutions, services, and cutting-edge bioinformatics and software, our unique approaches are solving complex problems, including chromatin topology analysis, small and large structural variant detection, de novo chromosome assembly, haplotype phasing, metagenomics, and microbiome analysis. Our customers are positively impacting the fields of epigenetics, developmental biology, cancer research, evolutionary biology, infectious disease, and more. Cantata Bio is based in Scotts Valley, California and Cambridge, Massachusetts. For more information on Cantata Bio, its technology, and offerings, visit www.cantatabio.com.

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. NASDAQ:CDNA About AlloSure® AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. http://www.allosure.com/ About AlloMap® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients. http://www.allomap.com/

CD Genomics is aiming at providing the research community with high quality Next Generation Sequencing, high throughput microarray services. Due to the demand for our services has being increased; CD Genomics has already updated its technology platform to mainstream NGS and microarray instruments. At present, our senior bioinformaticians have ever viewed more than ten thousands of trace files and accumulated abundant experience with our Illumina HiSeq2000/2500, Illumia Miseq, Ion Torrent PGM, PacBio RS and ABI 3730/3730XL analyzers. We continue to work hard to offer you the same dependable services to pharmaceutical and biotech companies, as well as academia and government agencies for the purpose of satisfying all your sequencing or array needs. In 2007, CD Genomics has expanded its services to molecular biology research and its development needs. We have become a service provider in sequencing, microarray analysis, library construction and genotyping. Our progress could not be achieved without our large group of client's support. Through nearly ten year's hard working and depend on our professional work team, we are proud of satisfying the needs of our clients both at home and abroad, which across more than 50 countries and districts. We always devote ourselves to providing you with the best and professional service.

Celemics is a Next Generation Sequencing (NGS) full solution provider based on target enrichment technology. We confidently offer custom target enrichment panels and high-quality pre-set panels, covering fields such as Inherited Diseases, Oncology, Immunology, and Pathogen Diagnostics. With 13 years of experience, we will provide the best solution for your Targeted Sequencing. [Products/Services] OncoRisk (Hereditary Cancer) | CancerScreen (Somatic Cancer) | Custom Target Enrichment Panel | Whole Exome Sequencing | Clinical Exome Sequencing | BRCA 1/2 | PharmacoScreen | Comprehensive Respiratory Virus | Agrigenomics

Cellecta provides HT loss-of-function genetic screening services for the discovery and functional characterization of novel therapeutic targets. We offer pooled lentiviral shRNA and CRISPR libraries, pooled library screening and analysis by NGS, targeted RNA-Seq for biomarker discovery, lentiviral reagents, and stable cDNA, shRNA, and CRISPR constructs and isogenic cell lines.

At Cerba Research we provide world-class clinical research to help life science companies successfully develop the predictive and precision medicines of the future and help people live healthier lives. We are committed to delivering the next generation of healthcare by transforming research and advancing health together. We support you with industry-leading excellence in oncology, virology, vaccine development, immunology, and cell and gene therapy, together with world-class deep specialty testing, from next generation sequencing to flow cytometry, molecular diagnostics, IHC & and spatial Omics, and bioinformatics. We are committed to helping you deliver the next generation of human-centric healthcare, by transforming research, and advancing health together. Uniquely, we combine the experience of specialty laboratories with the global reach of a central lab. We have a worldwide network of 1000 labs, hold data from over 85 million patients across five continents, and have the ability to sequence 1000-plus whole human genomes per week. This unparalleled approach to patient data gives you the opportunity to have one partner for all your test services, with consistent access and support across all clinical trial phases.

Champions Oncology, Inc. provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today's needs and innovating for tomorrow's challenges. At the core of our services is the Champions TumorGraft® (CTG) platform, a comprehensive, unique compendium of PDX models that preserve the biological characteristics of human tumors and are highly predictive of clinical outcomes. Services utilizing Champions TumorGrafts® PDX tumor models include evaluating tumor sensitivity/resistance to various single, combination, standard and novel chemotherapy agents, biomarker discovery and the identification of novel drug combinations. Champions TumorGraft® PDX models are procured through agreements our Clinical Collaboration Network, a series of renowned oncology institutions in the US and around the world, as well as through the company's Personalized Oncology Solutions business. Personalized Oncology Solutions assist clinical oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients' cancer tissues, as appropriate. Additionally, the company offers personalized PDX development, drug studies and genome sequencing, whereby physicians evaluate the effects of cancer drugs and understand the genetic makeup of each patient's tumor, enabling them to better select treatment regimens.

ChromaCode is deploying a solution for mid-density, multiplexed analysis, high-definition PCR or HDPCR​.COVID-19: EUA (06/2020) for its HDPCR SARS-CoV-2 Real-Time PCR

We are an early-stage biotech startup based in Santa Cruz. We are a small, motivated, multi-disciplinary team innovating in NGS sequencing technologies and DNA assay design for applications in molecular diagnostics with focus on liquid biopsies, FFPE and ancient DNA Interested in beta testing our single-stranded approach to NGS library prep? Get in touch! www.claretbio.com/contact We are always looking to build our team with seasoned scientists who want to be on the ground-level of ground-breaking technology.

Clarity Genomics provides consulting services for microbiome-metabolome data insights in clinical research. Using our global network of specialists and regional cloud storage and computing, we provide expertise in collection and preparation of microbiome and metabolome samples, data processing and analysis. We work closely with our clients to offer biological insights that empower the development of new microbiome products and therapies. Partnerships with leading research institutions ensure that your project receives relevant information utilizing technologies and techniques on the forefront of innovation.

Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs democratizes genomics applications to deliver increased clarity. Clear Labs’ turnkey platform accelerates outcomes and improves accuracy - from food-borne pathogens to infectious diseases, including SARS CoV-2. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow’s novel pathogens.

The company provides contract research services for molecular analysis in addition to clinical trial and bio-marker investigation studies. The company also provides laboratory studies for gene expression analysis, genomics and epigenetics.

CosmosID provides award-winning, end-to-end microbiome solutions. They offer NGS, Metabolomics, Bioinformatics, as well as the world's most advanced microbiome analysis software, CosmosID-HUB: Microbiome. The HUB relies on validated databases and algorithms specifically designed for maximum sensitivity, precision and lowest false positive rates. Unlike other solutions, CosmosID delivers strain-level results – we understand that the biologically informative and actionable unit in microbiology is not a genus or species, but ultimately a strain and its unique genetic and metabolic properties. CosmosID was founded in 2008 by Dr. Rita Colwell, former director of the National Science Foundation and currently Distinguished University Professor at the University of Maryland and Johns Hopkins University Bloomberg School of Public Health. To learn more please visit www.cosmosid.com.

Creative Genomics(CG) specializes in providing the services of DNA sequencing, genotyping and library construction in the global market. Our state-of-the-art sequencers including ABI3730xl, Roche 454 GS-FLX System and Illumina Solexa 1G Genome Analyzer make our customer-oriented DNA sequencing services to stand out with efficiency, reliability and flexibility. Coupled with a variety of high definition genotyping platforms such as Illumina BeadStation 500, Beadxpress and Sequenom, a full range of services from whole genome scans to targeted SNP genotyping can be provided with a high turnover rate. In addition, theyhave professional team members with extensive experience in library construction. Above all these, an in-house Laboratory Information Management System (LIMS) as well as manual basecalling by senior bioinfomaticians ensuresservices with the highest quality.

Daicel Arbor Biosciences is a development and manufacturing company founded by scientists to serve our peers in molecular biology applications. We are a passionate organization of scientists determined to deliver cost-effective, user-friendly products to researchers of genetics and synthetic biology. The Daicel Arbor Biosciences team prides itself on providing exceptional customer service and timely technical support to new or advanced users on our array of products. We routinely collaborate with our customers and research partners to develop innovative solutions to address their unique applications. From discussing the feasibility of a project to providing fast, reliable laboratory services, we are here to help.

The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases. With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.

DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.

We are a well-funded stealth biotech company backed by some of the most experienced operators and investors in the biotech industry. Our co-founders are highly experienced researchers, clinicians, and entrepreneurs, on a mission to improve precision medicine with cutting-edge genomic technology.

DLS is proud to be Hawaii's largest locally-owned clinical testing laboratory with a team of 800+ dedicated professionals. Our Microbiology Lab is the only clinical laboratory in Hawai'i with the WASPLab, a highly advanced specimen processor. Our Core Lab features a chemistry automation line that is the largest of its kind in the state. It also utilizes mobile robots that efficiently deliver samples between processing stations. We know that when it comes to the wide variety of lab tests we perform, quick, accurate results and analyses improve health and save lives. At DLS, we are committed to excellence in laboratory science and stand by our guiding values, I.C.A.R.E.: I - Innovation C - Care A - Aloha R - Respect E - Excellence We work closely and collaboratively with physicians, medical groups, hospitals and clinics. Our employees are what makes DLS a successful company and we strive to provide an environment of growth and professional development for our versatile and high-performing workforce. Beyond lab results, we build relationships and create collaborative partnerships with the communities we serve. No matter what your position is at DLS—medical technologist, medical laboratory technician, technical laboratory assistant, phlebotomist, systems engineer or patient account representative—your role will impact patient health. When it comes to living in Hawai‘i, we at DLS are committed to making our newest members feel at home with guidance and support. We believe in a healthy work-life balance, and we want our team members to take full advantage of our islands' natural beauty and great year-round weather.

A unique laboratory providing accurate and actionable results in one day for infectious diseases and antibiotic resistance genes utilizing innovative molecular technologies, including proprietary TEM-PCR™. Eurofins Diatherix distinctions: - Delivers one-day results - Identifies bacteria regardless of recent antibiotic use - Offers simplicity of single-sample collection - Identifies difficult-to-culture pathogens - Yields a high level of sensitivity and specificity

DKP Genomics is a bioinformatics CRO. We provide top-quality computational biology analysis and bioinformatics infrastructure support to biotechnology, pharma, and agricultural companies and to research foundations. With nearly 15 years of experience in both biotech and major pharma, we're well versed in the standard analyses as well as advanced analyses to help identify targets, biomarkers, compound mechanisms, and advance the understanding of biological pathways and systems in multiple areas: microbial systems, diabetes / obesity, frailty, cancer, and neuroscience. More information can be found at http://www.dkpgenomics.com

DNASTAR is a global software company that has been meeting the needs of life scientists for over 30 years by providing innovative and easy-to-use desktop software tools for today's life scientists. DNASTAR Lasergene provides all the software you need for molecular biology, genomics, and structural biology research and is available as a complete package or as individual suites.

DNA Technologies presents a unique anti-counterfeiting and brand protection solution to the marketplace through its combination of synthetic, DNA-laced security markers. We are dedicated to helping manufacturers, authenticators, license & trademark holders, governments and publishers worldwide eliminate the production and distribution of counterfeit goods. DNA Technologies uses expert knowledge to construct unique, synthetic DNA sequences that can encode company and product-specific information into inks, dyes and resins, to provide the ultimate security marker – the DNA MatrixTM. DNA Technologies has become the recognized leader in providing security marking and unequalled protection for valuable products, brands and intellectual property. This patented and proprietary technology has been used to protect the products and brands of Thomas Kinkade, Major League Baseball, the National Hockey League, the Super Bowl, Hanna-Barbera, BRL Hardy's Wines and the 2000 Sydney Olympics.

Eclipsebio develops first-in-class technologies, analyses, and platforms for the development of tomorrow’s RNA-based and RNA-targeting therapies. With our extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, we provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. We offer our solutions as end-to-end partnerships, including custom assay development, for biopharma and biotech companies and as a la carte services. Our areas of support include: - The optimization and characterization of RNA-based vaccines and therapeutics through our eMERGE platform - Multiomic characterization of small molecule and small oligonucleotide targets - Robust validation of on-target, and the identification of off-target, effects from small molecule and small oligonucleotide drugs - Deep profiling of RNA for groundbreaking discoveries in academic research Contact us today to discover how we can provide you with the insights needed for RNA success.

EdgeBio has a team of experienced research professionals that are knowledgeable in next generation sequencing technologies and applications. From library preparation through data analysis, EdgeBio representatives are there to discuss your project on a custom basis to ensure that you receive the results you need for your research. Follow us on Twitter at: https://twitter.com/EdgeBio

Edico Genome is a biotechnology company that specializes in developing cutting edge solutions for genomic sequencing analysis to provide unprecedented speed, scale, and accuracy.

Element Biosciences is a multi-disciplinary startup focused on developinggenetic analysis tools for the research and diagnostic markets.

Elim Biopharmaceuticals, Inc. is a leading life science service company for the biotech, pharmaceutical, and medical communities, offering a range of services from sequencing to synthesis, including drug quantification.

We are a skincare startup founded in 2018 in San Francisco. We combat the rise of skin conditions and sensitive skin by building a world in which beauty and science work together to produce optimal health. We develop clean, science-backed products that respect our skin's natural ecosystem. Discover our B2B microbiome tech platform @hellobiome. Our founder, Elsa Jungman, has a Ph.D. with strong expertise in dermatology, microbiome and clean beauty. She is a UCSF, L'Oréal and AOBiome alumna.

We are a biotechnology company offering end-to-end solutions in molecular diagnostic for oncology and hematology by providing hardware, reagents and software. Starting from automated nucleic acid extraction and culminating in genomic interpretation with its proprietary software embedded throughout entire workflow, EntroGen solutions are designed to be accurate, economic and scalable. EntroGen sells CRCdx®, a U.S. FDA-approved product.

Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic’s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic’s goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians with real-time information to guide treatment choices. For more information please contact us at info@epicsciences.com

Everlum Bio is pioneering a novel approach to drug development for rare diseases. As opposed to working on a single disease we are doing "Drug Development as a Service". We are relentlessly focused on innovating the drug development process. Ultimately we believe this approach will usher in a personalized/precision medicine revolution.

Express Gene Molecular Diagnostics Laboratory is a CLIA CLIA-certified laboratory located in Miami, Florida. Our focus is genetic testing and we offer several important genetic tests, including pharmacogenomics tests. Pharmacogenetic (PGx) testing is a type of genetic test that assesses a patient's risk of an adverse response or likelihood to respond to a given drug. This gives healthcare providers insight into what medications to use for a given condition. The PGx test allows physicians to make informed, science-based drug selections and appropriately adjust the dosing.

Challenges with physical cell isolation limit adoption of single-cell sequencing. So we figured out how to prepare complete libraries within intact cells.

Floragenex is an biotechnology company that provides innovative solutions for genomic analysis in human, plant and animal systems. With multiple offices located on the US Pacific coast, our technologies allow investigation of genomes at unprecedented levels for academic, governmental and commercial researchers worldwide.

Fluent BioSciences, an Illumina company, is a biotechnology company with a mission to accelerate the understanding of biology and disease through simple, cost effective and scalable solutions for every laboratory from research to the clinic. Fluent’s breakthrough Pre-templated Instant Partitions (PIPseq™) technology enables near-instantaneous self-assembly of individual cells or molecules into millions of uniform partitions without the need for complex instrumentation or expensive consumables. This powerful platform enables extremely sensitive and unbiased preparation of proteins and nucleic acids for a broad range of discovery and disease applications including single-cell RNA sequencing (scRNA-Seq).

FORMULATRIX® supplies innovative software and robotic automation solutions to the life science industry including the leading pharmaceutical companies and academic research institutions around the world. We collaborate with researchers to simplify scientific workflows such as sample preparation and analysis by designing solutions without boundaries and bringing novel cutting-edge technology into the laboratory. We are committed to researchers, their labs, and to the scientific discoveries that will improve the lives of generations to come.

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit us at www.FoundationMedicine.com or follow @FoundationATCG on Twitter. Community Guidelines: bit.ly/FMICommunityGuidelines

Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us. Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike. - Our Products & Services - Fulgent Genetics https://www.fulgentgenetics.com/ Fulgent Oncology https://fulgentoncology.com/ Fulgent BioPharma https://biopharma.fulgent.com/ Picture Genetics https://picturegenetics.com/ HelioLiver https://www.helioliver.com/ Fulgent is a CLIA-certified and CAP-accredited laboratory. _____________ NASDAQ: FLGT

We are building the largest longitudinal cohort in the Americas to power precision health at scale for all. Our goal is to improve diagnostic testing and accelerate drug discovery in diverse underserved populations. We are focused on Latin America and our diaspora populations throughout the world including founder populations in the Americas, those who identify as Hispanic/Latino, Black or African American, Asian American, American Indian/Alaska Native, First Nations, and Native Hawaiian/Pacific Islander as well as people who self identify as belonging to two or more of these groups. Core to our mission is building trust with the communities we serve and long term partnerships with communities, researchers, clinicians, and most of all patients and their families. This is your biobank and for the benefit of all. If we build it, we can decide how the data are used. And no one is going to do it for us, so let’s roll up our sleeves and “time to build.” Join us! Este biobanco es tuyo y para todo el continente porque si lo construimos juntos podemos decidir cómo se usan los datos y con que fines. Nadie lo va a hacer por nosotros así que bienvenido a nuestro esfuerzo. Unete!

Gencove creates high-volume, cost-sensitive sequencing software-as-a-service to help academic, agriculture, biotech, diagnostic, and pharmaceutical companies get all the genomic information they need to make life-saving discoveries.

Gene Codes Corporation is an international software firm specializing in bioinformatics software for DNA sequence analysis. Gene Codes'​ scientist-friendly software tools hold the dominant share in the DNA sequencing sector and are unrivaled in forensic DNA identification for mass fatalities. Gene Codes'​ success is built on customer-driven product development, combining the latest programming techniques, rigorous quality control and an open dialogue with customers to produce products of the utmost usability and industry relevance. Since 1991, when Gene Codes first introduced its groundbreaking Sequencher software for sequence analysis, we have served the needs of industrial, academic and government-based biotechnology groups across the globe. As the popularity of Sequencher has grown, so has the company. Gene Codes is a motivated, enthusiastic, high-energy organization based in Ann Arbor, with offices in New York City and in Brighton, England. Gene Codes'​ corporate culture values flexible collaboration, shared responsibility, and dynamic change.

Genemarkers is a Kalamazoo, Michigan-based contract services laboratory specializing in genomics research and molecular testing services, with a primary focus on consumer products, dermatology, skin-related research and therapeutics.. Founded in 2008 by former professor and neuroscientist Dr. Anna Langerveld, Genemarkers has proven its expertise through collaborations with cosmetic, pharmaceutical, and academic research institutions over the years. Taking pride in providing actionable, high quality data and customer service, Genemarkers' CLIA-certified and CAP-accredited laboratory has the ability to support a wide range of projects throughout discovery and development including advanced cellular models/exposures (e.g., dermal/transdermal, hepatic/extrahepatic, neuronal and bronchial/inhalation) and next generation bioinformatics and computational modeling.

Geneoscopy is a life sciences company with the mission to empower patients and providers to transform gastrointestinal health through innovative diagnostics. Geneoscopy's lead diagnostic uses stool-derived eukaryotic RNA (seRNA) to detect colorectal cancer and precancerous adenomas. This device was awarded a Breakthrough Device Designation from the FDA for its ability to reduce morbidity associated with colorectal cancer through advanced adenoma detection. Our initial prospective clinical study demonstrates that the diagnostic can detect these lesions with greater sensitivity than all existing noninvasive screening tests, thereby, serve as a potential aid in early detection and prevention of cancer. Geneoscopy is also developing diagnostics for the diagnosis and management of inflammatory bowel disease in partnership with biopharmaceutical companies and leading academic research institutions.

GENEWIZ from Azenta Life Sciences Company, is a leading global genomics service provider serving thousands of researchers in institutions worldwide. GENEWIZ offers a suite of solutions including DNA synthesis, sanger sequencing and next generation sequencing to accelerate antibody discovery and development research. Other services also include bioinformatics, GLP regulatory, and clinical services. From the company’s founding, GENEWIZ has maintained an unwavering commitment to providing customers with the best combination of quality, service, and value. Easily accessible around the world, GENEWIZ is the preferred partner at leading academic, pharmaceutical, biotechnology, agricultural, government, and clinical institutions. At GENEWIZ, it is our mission to contribute to the advancement of life sciences and technologies. Together with our clients, we can make a difference in the pursuit of scientific discoveries, better healthcare, a greener environment, and abundant food supplies. Our goal is to be the best in the world and the best for the world. Headquartered in Leipzig, Germany and South Plainfield, NJ, GENEWIZ has additional locations in Takeley, United Kingdom; Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; San Francisco, CA; Seattle, WA, Beijing, China; Suzhou, China; and Tokyo, Japan.

A premier research institution providing global genomic profiling and molecular diagnostics services to academic centers, pharmaceutical and biotech industry, oncologists, and pathologists with innovative diagnostic, prognostic, predictive, and personalized testing. Genome Explorations, a Tesis Biosciences company, is a state of the art CLIA certified GLP compliant Lab providing NextGen sequencing, Genotyping, Gene Expression and microRNA profiling services. Our Clients range from Fortune 500 Pharmaceutical and Biotech to Individual Investigators at Academic institutes and are located worldwide. Our experienced scientists work one-on-one with researchers and clinicians to provide a ‘Complete Solution' for all their Research and Clinical needs, from experimental design to in-depth data analysis and advanced bioinformatics. Genome Explorations also offers ‘Complete Solutions' for challenging specimens, such as whole blood and FFPE tissues.

Harvard University is devoted to excellence in teaching, learning, and research, and to developing leaders in many disciplines who make a difference globally. Founded in 1636, Harvard is the oldest institution of higher learning in the United States. The official flagship Harvard social media channels are maintained by Harvard Public Affairs and Communications and aim to provide access to the people, places, events, news and research at our Institution. We ask that all visitors to Harvard's digital spaces be civil to one another and to the site editors. Personal attacks, profanity, commercial solicitations, spam, misinformation or other inappropriate contributions are grounds for comment removal. We ask that you stay on topic when contributing to a discussion and refrain from duplicate posts. Hateful or discriminatory comments regarding race, ethnicity, religion, gender, disability, sexual orientation, or political beliefs will not be tolerated. The page administrators reserve the right to delete inappropriate or abusive comments and to permanently ban or block users from the Harvard social media accounts.

The mTilda HLA Laboratory Information Management System (LIMS) is an enterprise Histocompatibility & Immunogenetics software platform. mTilda includes scalable HLA-specific modules that encompass specimen workflow, patient and data management, inventory control, reagent vendor connectivity, institutional EMR/LIS interoperability, and customizable reporting.

The Faculty of the Horae Gene Therapy Center is dedicated to developing therapeutic approaches for rare inherited disease for which there are no cures. They utilize state of the art technologies to correct the genetic mutations underlying the diseases. The Center focuses on AAT Deficiency, Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease), Canavan Disease, Cystic Fibrosis, Tay-Sachs & Sandoff diseases, Retinitis Pigmentosa, Huntington's disease, Hypercholesterimia, and Cardiac Arrhythmia.The Center operates under the umbrella of the Advanced Therapeutics Cluster (ATC) of UMass, whose mission is to apply knowledge flowing from the latest biomedical discoveries, develop new ways to treat diseases, and drive those therapies into clinical trials.

Welcome to the cutting edge of spatial biology and translational research! We're a specialized Contract Research Organization (CRO) and a CLIA High Complexity-certified, CAP-accredited clinical diagnostic laboratory, dedicated to empowering your scientific pursuits! Our focus lies in the field of spatial biology, spatial phenotyping, tumor micro-environment mapping, multiplex immunofluorescence (mIF), IHC, histology, digital pathology, digital and quantitative PCR (dPCR and qPCR), as well as next-generation sequencing (NGS). We use cutting-edge equipment to provide next-generation tissue pathology services, including high-resolution imaging and comprehensive analysis of tissue samples. Our collaborators include scientific teams across the drug development pipeline. Whether you're trying to identify predictive biomarkers or stratify patients, we can help you study the intricate interplay between cells and their surroundings, unlock insights into disease mechanisms, and uncover novel targets. Our team of experts can provide you with end-to-end support including method development and validation, sample testing, regulatory compliance, and clinical trial logistics.

IGENOMIX USA is a biotechnology company that specializes in genetic testing services for reproductive health and fertility.

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

INanoBio’s mission is to develop high-accuracy early stage disease diagnostics using transformative nano-biotechnology platforms and machine learning. Extract systems scale information from complex disease biology, identify and detect disease specific molecular biomarkers, signatures at prodromal or pre-symptomatic stages. We believe most diseases can be detected early, enabling early personalized therapeutic intervention to preempt full development of diseases, ushering in preemptive medicine.

Inform Diagnostics, a Fulgent Genetics Company, is a leading pathology laboratory trusted by clinicians throughout the U.S. We provide timely, accurate and definitive patient diagnoses in the fields of dermatopathology, gastrointestinal pathology, hematopathology, neuropathology, breast pathology, molecular diagnostics (Covid-19 testing), and genitourinary pathology. Working for Inform Diagnostics means you will contribute alongside top multidisciplinary talent in an environment with cutting-edge tools and breakthrough technologies. It is a place where people are passionate in their belief that every patient deserves the right answer. Driven by an unwavering dedication to quality, Inform Diagnostics profoundly impacts patient care, one diagnosis at a time. The company has state-of-the-art laboratories in Boston, Dallas, New York City, and Phoenix. Visit us at informdx.com.  

Ingenio Diagnostics (ID), a Genesis Drug Discovery and Development (GD3) Member Company, combines experience in Pharmaceutical, Biotechnology, and CRO services with a clinical diagnostic laboratory's licensure and accreditation. We deliver clinical diagnostic laboratory services and specialty testing with the additional benefit of dedicated quality assurance & quality control division. Our highly-skilled team of scientists, clinical, and operations personnel have extensive experience analyzing a wide variety of patient specimen types, spanning multiple analytical platforms in many therapeutic areas.

Insight Genetics provides advanced diagnostic solutions that enable personalized cancer care and improve patient outcomes. We have a portfolio of assays that detect specific cancer biomarkers and an innovative platform technology for assay development. Our products and services have application in translational research, clinical diagnostics and drug discovery.

Integrated DNA Technologies, Inc. (IDT) develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP services, IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as the industry leader in custom nucleic acid manufacture, serving over 130,000 life sciences researchers. IDT was founded in 1987 and has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Research Triangle Park, North Carolina, USA; Ann Arbor, Michigan, USA; Leuven, Belgium; and Singapore. For more information, please visit www.idtdna.com and follow on Twitter, LinkedIn, Facebook, YouTube, and Instagram.

Intelliseq provides state of the art solutions for next generation sequencing. A team of passionate and skilled bioinformaticians, geneticists and molecular biologists approaches next generation DNA sequencing challenges with creativity and flexibility.

Intus Bio is using its proprietary high-resolution, high-throughput assay and analysis technology to identify bacteria and deliver answers about the microbiome, with unprecedented detail, accuracy and scale. The company is powering groundbreaking research, discovery and services with clients and partners across the global pharmaceutical, diagnostic, and testing industries; is active in health, agricultural, and environmental fields; and continues to develop new and innovative partnerships, technologies, and applications.

Ipsum Diagnostics is a nationally acclaimed molecular diagnostics laboratory, renowned for its expertise in identifying infectious disease pathogens and antibiotic resistance genes. Our molecular panels leverage the power of polymerase chain reaction (PCR) technology and provide fast results for more effective treatment that leads to improved patient outcomes. Located in Atlanta, GA, our state-of-the-art laboratory specializes in molecular and anatomical pathology. We accommodate workflow needs by providing services such as customized reports, statistical analysis of patients with different treatment plans, and meaningful data to assess overall treatment performance amongst patient populations. Our comprehensive and succinct patient reports can be made available via EMR integration, portal access, fax, or our easy to use mobile or tablet app. Ipsum's software capabilities allow for a superior customized experience, with the highest quality standards that will have your reports completed promptly and efficiently. Ipsum Diagnostics creates a true partnership environment between Provider, Patient, and Laboratory. For locations needing a UPS pickup please follow the below instructions: 1. Call (800) PICKUPS 2. When prompted reply "Schedule a pick"​ 3. You will be asked for your phone number 4. Be prepared to have tracking number ready to provide 5. Provide address of pick up with a time frame UPS Phone Center Shortcuts: https://www.ups.com/us/en/contact/ivr-Popup.page?

iRepertoire was the first to develop and commercialize immune repertoire sequencing technology and products. iRepertoire uses immune repertoire sequencing technology to access the body’s immunological memory, or “logbook” of all past infection and disease. Sequencing the immune repertoire can yield insights into the nature of the body’s immune response to disease and infection. The future market for iRepertoire will be in clinical and research applications that require immune assessment such as drug treatment monitoring, identification of minimal residual disease (MRD), immune monitoring after stem cell transplantation, vaccine studies, and biomarker development.  iRepertoire provides primer kits and amplification to sequencing services to examine the TCR and BCR immune diversity in both humans and mice. iRepertoire also offers access to its proprietary repertoire analysis tools with the purchase of its regent systems.  iRepertoire’s reagent systems allow researchers to easily and inexpensively generate their own Next Generation Sequencing libraries in the convenience of their laboratory and analyze their data with the iRepertoire’s proprietary software pipeline at no additional cost.This year, iRepertoire has launched automated immune repertoire amplification and extraction on their sister company’s iC-processor (iCubate, Inc.). iRepertoire is proud to be a part of the non-profit initiative R10K, or Repertoire 10,000, with the HudsonAlpha Institute for Biotechnology, which aims to study the immune repertoire of 100 different diseases. The company has developed two key indices to describe the immune repertoire, i.e., the diversity index and the sharing index. These indices allow iRepertoire to identify disease specific signatures for diagnosis, prognosis, and treatment guidance.

The mission of the Department of Energy is to ensure America's security and prosperity by addressing its energy, environmental, and nuclear challenges through transformative science and technology solutions. Goal 1: Science and Energy — Advance foundational science, innovate energy technologies, and inform data driven policies that enhance U.S. economic growth and job creation, energy security, and environmental quality. Goal 2: Nuclear Security — Strengthen national security by maintaining and modernizing the nuclear stockpile and nuclear security infrastructure, reducing global nuclear threats, providing for nuclear propulsion, improving physical and cybersecurity, and strengthening key science, technology, and engineering capabilities Goal 3: Management and Performance — Position the Department of Energy to meet the challenges of the 21st century and the nation's Manhattan Project and Cold War legacy responsibilities by employing effective management and refining operational and support capabilities to pursue departmental missions

Jumpcode Genomics is changing the way scientists see their samples with our proprietary CRISPRclean® technology. Combining CRISPR-based technology and next-generation sequencing (NGS) they can now search for and find novel signals they previously couldn't. Our technology removes unwanted sequences, allowing researchers worldwide to extract greater insights. By increasing sensitivity and allowing access to a range of sample types, we're broadening the understanding of human biology in fields from research to clinical applications including infectious disease and oncology.

At Kallyope, we focus on big health challenges that matter to patients and families. We aim to discover and develop effective, easy to use, and well-tolerated oral agents addressing metabolic, neurological, and gastrointestinal diseases. Inside every human body is a complex, unexplored network of metabolic, neurological, and gastrointestinal interconnections. Our scientists are unlocking the mysteries of this network to develop oral therapies for obesity and diabetes; neurological disorders, including migraine; and gastrointestinal disease, including celiac disease. Based in New York City, we are home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development. Together, we are leveraging multiple sophisticated technologies and internally-developed capabilities to bring fundamentally new solutions to some of the most pressing unmet needs in human health.

SeraCare, part of LGC's Clinical Diagnostics Division, enables the promise of precision medicine by advancing the understanding of disease and providing assurance of the diagnostic result. Our innovative tools and technologies not only ensure the safe, effective, and accurate performance of diagnostic assays but also establish a framework for regulating, compiling, and interpreting data from precision diagnostics. Our portfolio includes a broad range of products such as quality control technologies, disease-state specimens and tissues for research and development, processed biological materials, and immunoassay reagents.

Headquartered in Somerset, NJ with offices around the world, LabVantage Solutions, Inc. provides laboratories with a comprehensive portfolio of informatics products and services, including LIMS (Laboratory Information Management System), integrated electronic laboratory notebook (ELN) and business intelligence. Our industry-leading solutions and services are the result of 35+ years of experience in laboratory informatics. We leverage that knowledge with state-of-the-art technology to help organizations redefine and optimize the way their laboratories conduct business. LabVantage has a solid track record of delivering return on investment to laboratories of all sizes. Our capabilities extend to legacy system migration, global laboratory harmonization, and laboratory business intelligence derived from disparate sites and systems. LabVantage delivers the best technical and domain expertise available to help you drive the success of your business. To find out more, visit us at: http://www.labvantage.com.

SVBio is now LIfecode, Inc. We are focused on the genetic basis of human disease. With an initial focus in oncology, Lifecode is committed to improving the lives of patients through molecular information that is concise, accurate and actionable. The long-term vision of Lifecode is to revolutionize the world of genomic medicine.

LifeMap Sciences offers a leading integrated biomedical knowledgebase for empowered life sciences research and precision medicine, and a powerful advertising products for research reagents. Our products are used by more than 5 million researchers from both academia and the biopharma industry. GeneCards (www.genecards.org) is a searchable, integrative database that provides comprehensive, user-friendly information on all annotated and predicted human genes. The knowledgebase automatically integrates gene-centric data from ~150 web sources, including genomic, transcriptomic, proteomic, genetic, clinical and functional information. MalaCards (www.malacards.org) is an integrated database of human maladies and their annotations, modelled on the architecture and richness of the popular GeneCards database of human genes. Today, it offers information about 22,060 disease entries, consolidated from 74 sources

Loop Genomics technology transforms short-read DNA sequencers into high-throughput, long-read, single-molecule DNA sequencing machines.

Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients. EsoGuard is commercialized in the U.S. as a Laboratory Developed Test (LDT). EsoCheck is commercialized in the U.S. as a 510(k)-cleared esophageal cell collection device. EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device designation and is the subject of two large, actively enrolling, international multicenter clinical trials to support FDA PMA approval. Lucid is building a network of Lucid Test Centers where at-risk GERD patients can undergo the EsoCheck procedure for EsoGuard testing.

Machaon Diagnostics is a clinical reference laboratory and contract research organization (CRO), specializing in the diagnosis, treatment and monitoring of hemostatic and thrombotic conditions, complement-mediated disorders and rare genetic diseases. Machaon Diagnostics has a mission to save more lives with lab tests. Started as a collaboration of four laboratory scientists, we have rapidly grown into a dedicated group of clinicians, scientists, consultants and technologists. Collectively, the Machaon Diagnostics team brings over 400+ years of expertise to the field of laboratory testing. Our esoteric and routine testing menu applies to a wide variety of disorders and clinical trials and therefore draws attention from both a national and an international clientele. Our clients include community hospitals, university medical centers, clinics, commercial laboratories and research laboratories, as well as biotechnology, pharmaceutical and medical device companies. Machaon brings custom solutions to hospitals, laboratories and trial sponsors. Our primary goal is to provide quality testing (CAP/CLIA, GLP, GCP) at industry-leading speed.

At Magbio Genomics, we are dedicated to advancing genetic research with cutting-edge products designed to safeguard the integrity of bio-samples while efficiently isolating circulating biomarkers. Specializing in human genetic research, including cancer studies and non-invasive prenatal testing (NIPT), our innovative solutions empower researchers to unlock invaluable insights. At the heart of our operations lies our core platform, enabling seamless nucleic acid sequencing methods such as Sanger and Next Generation Sequencing (NGS) across both manual and automated workflows. Our commitment extends beyond product development; it's about facilitating quality data generation at an accelerated pace and an accessible cost. Driven by our corporate mission, we strive to empower our customers to achieve their research goals efficiently and effectively, propelling scientific discoveries forward with Magbio Genomics by their side.

The MU Genomics and Bioinformatics cores provide centralized genomic, bioinformatic and biostatistical services to investigators at universities and colleges throughout the state. The Genomics Core currently provides five services to research programs and individual investigators:high throughput next generation sequencing (NGS) to support whole genome, whole exome, RNA-Seq, single cell RNA-Seq, microbiome and global chromatin and methylation studiesbiostatistical and bioinformatic support for NGS projectsaccess to DNA/RNA sequence analysis softwareautomated Sanger DNA sequencing, genotyping and RNA/DNA quality assessmentaccess to shared instrumentation such as plate readers, real time thermal cyclers, Agilent Bioanalyzers, fluorimeters, and spectrophotometers

MassBiologicsis a non-profit FDA-licensed manufacturer of vaccines. For over 100 years, MassBiologics has worked to improve public health through applied research, development and production of biologic products, including vaccines, plasma derivatives and more recently, monoclonal antibodies. MassBiologics currently manufactures Tetanus and Diptheria Toxoids, Adsorbed (Td) vaccine and distributes them nationwide.

Matchstick’s premier product, PIXUL (forPIXelatedULtrasound), is a tool that processes each and every well of a 96-well microplate consistently and quickly.

Established in 1998, Molecular Cloning Laboratories (MCLAB) is a leader in providing genomic research consumables and services to the Life Sciences community. MCLAB provides cost-effective consumables and reagents, focusing on first generation as well as next-generation sequencing and DNA fragment analysis. We manufacture a large selection of molecular biology related products, including antibodies, biochemical reagents, cloning kits, enzymes, PCR kits, protein gels & solutions and more. With a team of over twenty experienced scientists and over six decades of experience, MCLAB is committed to offering first-rate services to researchers. We specialize in the field of genomics, with experts in DNA sequencing, fermentation, fragment analysis, molecular cloning, over-expression, protein purification, and protein synthesis. MCLAB has offices in China and distributors all around the world, including Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Germany, Hungary, Greece, India, Israel, Poland, New Zealand, Turkey, United Kingdom and Vietnam.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian's diagnostic products are used outside of the human body and require little or no special equipment. The Company's diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agri-bio industries engaged in research. Many companies also utilize Meridian's products as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers, and agri-bio companies in more than 70 countries around the world. Meridian's website address is www.meridianbioscience.com.

Metabiomics has developed a new type of microbiome diagnostic test for early detection and monitoring of polymicrobial and immunological diseases such as inflammatory bowel disease, colon cancer, HIV infection, alcoholic liver disease, and others that are non-invasive, lower cost, more sensitive and accurate than currently available diagnostic procedures. For the past 10 years, Metabiomics has been a pioneer in human microbiome research specializing in functional metagenomics and systems biology applied to advances in microbial DNA sequencing methods, clinical research, and in vitro diagnostics. Our on-going clinical research is unraveling some of the secret relationships between human microbial communities, immunology, and health. Our research collaborations with Diversigen, the Harvard Chan School of Medicine, Penn State University and George Mason University Microbiome Analysis Center and several medical research institutions are focusing on microbial biomarkers and immunological responses in intestinal dysbiosis, colon disease and cancer, liver disease, and other immunological diseases.

Microbe Detectives, a WaterTrust business, harnesses the power of modern DNA technology to analyze water and wastewater systems in municipal, industrial and agriculture markets. We empower leaders in facilities, technology, and service with knowledge about their water systems that is unprecedented. This translates into improved protection of human health, capital assets, water resources, and the environment at reduced costs. The company is a 2014 graduate of the Water Council's BREW accelerator, winner of the 2015 Wisconsin Innovation Awards and 2017 WEF Gascoigne Award, host of the 2017 Microbiome Water Summit, and was selected to participate in the 2018 WEFTEC/BlueTech Research Innovation Showcase.

MicroGenDX provides qPCR+NGS sequencing for the detection of infectious diseases. The American Medical Association (AMA) and Medicare have issued a billing code to MicroGenDX to provide this testing service, recognizing this technology as medically necessary. MicroGenDX is trusted by over 39,000 physicians worldwide and has helped over 900,000 patients with diagnostic testing for their chronic and life-threatening infections. MicroGenDX is a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvements Amendments (CLIA) licensed clinical laboratory. Tens of thousands of patients with chronic and often life-threatening infections have benefited from MicroGenDX's work. MicroGenDX's NGS technology offers several advantages over traditional culture-based methods for identifying microorganisms. It can detect a wider range of microorganisms, including those that are difficult to culture or grow in a laboratory. It also provides more accurate and comprehensive results, as it can detect multiple microorganisms in a single sample and identify them at the species or strain level. Additionally, NGS technology is faster than traditional methods, allowing for quicker diagnosis and treatment decisions.  MicroGenDX's testing services are used in a variety of settings, including hospitals, long-term care facilities, dental offices, and veterinary clinics. Their technology has been applied to a wide range of clinical conditions, including chronic wounds, orthopedic infections, respiratory infections, and urinary tract infections, among others.

Overview: To provide “best in class” genomic services for supporting our partner’s R&D capabilities solutions in the agriculture (plant and animal), pharmaceutical and industrial biotech industries. Experience: MOgene was formed in 2004, by industry leaders in genomic research. Over the years, the experienced team at MOgene have established themselves a solid reputation within the industry as the “go to” genomics service provider for academic, government and industrial research groups and institutions. Multiple studies have been presented and published in leading scientific journals, based on the genomic services provided by MOgene. Providing Results: The scientists at MOgene have years of experience collaborating with scientists in multiple biotech industries to provide solutions for their research. There have been over 100 publications from both large and small research companies utilizing data from MOgene services. Specialties: PacBio Sequel, Illumina Next Gen Sequencing, MicroArrays, QuantiGene and ProCarta Multiplex Assays, Nucleic Acid Extraction, qPCR, Clinical assays utilizing Arrays and NGS, plus full bioinformatics capabilities.

Develops the LoopCap,™ a 4-step NGS workflow that removes the need for conventional library prep and generates a targeted, sequencer-ready library of molecules representing genomic regions of interest in a highly redundant manner.

Monogram Biosciences, a LabCorp company, is a leader in developing and commercializing innovative products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases. Our molecular diagnostics and testing services enable Healthcare providers to optimize treatment regimens for their patients to lead to better outcomes and reduced costs by matching the underlying molecular elements of an individual patient's disease to the drug best able to affect those elements. Further, we work with pharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics more efficiently by providing enhanced patient selection and monitoring capabilities throughout the development process. We have developed HIV tests, or assays, to help make the complexities of antiretroviral therapy easier to manage. We have also developed oncology products to help accelerate the development of targeted cancer therapeutics.

Murrieta Genomics is dedicated to advancing the use of genomic sequencing in precision medicine, agriculture, forensics, veterinary and direct to consumer applications by offering entrepreneurs access to the specialized equipment, know-how and mentors that can transform research into commercial enterprise. We are a true incubator, offering dedicated bench space to fledgling companies at basically zero cost, helping them to define their business model and validate their science, and then investing in the companies that "graduate" the incubator. We are located in the 16,000 square foot Murrieta Innovation Center in Southern California, in close proximity to Los Angeles, San Diego and Orange County. We welcome inquiries from researchers, entrepreneurs, scientists, investors, and business professionals who share our passion for advancing science and sparking economic development.

Electronic Genome Mapping Setting a new standard in structural variant analysis Nabsys, the pioneer of electronic genome mapping (EGM), uses solid-state nanodetectors to survey long DNA molecules to construct high-density maps with long-range information required to detect structural variants (SVs). Unlike other DNA mapping technologies that rely on the use of expensive optical imaging or fluorescent labels whose resolution is inherently limited by light diffraction, EGM identifies tags in close proximity therebye producing superior resolution. This high-density information makes it possible to identify both balanced and unbalanced SVs as small as 300 bp, in addition to larger chromosomal aberrations and genetic variation missed by next-generation sequencing. EGM involves simple, intuitive workflows eliminating the need for cytogenetics technical expertise, while delivering on the promise of easy-to-use, accurate, low-cost, whole-genome SV analysis. Visit the new Nabsys: https://nabsys.com/ Meet the OhmX™ Platform: Explore the genome in high-resolution. From sample prep through analysis, the OhmX end-to-end solution allows you to detect balanced and unbalanced events and a broad range of structural variants with precision. High Resolution Detection of SVs as small as 300 bp with >100 kb read lengths Low Cost Low instrument and consumable costs compared to other technologies Small Footprint Entire platform fits within 30"x17" saving valuable benchtop space Easy to Operate Easy sample prep, automated run monitoring & minimal hands-on time Accessible Analytics Web-based UI for data mining SVs via Human Chromosome Explorer™ powered by Hitachi High Tech

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.

Nevada's land-grant university founded in 1874, the University of Nevada, Reno has an enrollment of more than 21,000 students. The University is home to one of the country's largest study-abroad programs and the state's medical school, and offers outreach and education programs in all Nevada counties. Specialties earth sciences, engineering, seismology, geology, journalism, biochemistry, chemistry, physics, gaming studies, basque studies, business administration

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene delivers unsurpassed data quality to support our customers’ research goals. We are a world leader in NGS services, with thousands of employees and multiple locations across the globe. Novogene has strong scientific expertise and experience with 45 NGS-related patents, as well as over 950 SCI articles with a total impact factor of more than 7970, including publications in first tiers journals such as Cell, Nature and Science. The UC Davis location of Novogene Corporation Inc. was opened in early 2016. We utilize Illumina platform to serve customers in North and South America, and we also offer PacBio and Nanopore services. Novogene Corporation Inc. is proud to have collaborated with scientists from the USA, Canada, Brazil, Colombia, Mexico, and so many more. We are excited to see this global collaboration and partnership growing.

The NuProbe team has pioneered the development of a unique and novel PCR-based enrichment method called Blocker Displacement Amplification (BDA). The BDA technology enables the selective amplification of low abundant sequence variants (SNV and indels) in a background of wildtype DNA.

OMICS USA is an independent laboratory that offers testing services for allergens, chemical Residue, DNA/GMO, FDA Import Detention Testing, food safety, inspection services, microbiology, mycotoxins, nutrition, US EPA GLP (Good Laboratory Practices)

Oregon State University continues to advance its 150-year mission to provide access to a high-quality education as Oregon's largest and only statewide public research university.

At PacBio, we’re devoted to empowering you. Pioneering the future through biology takes vision. You have to look beyond the status quo to what’s possible. We know your vision can reveal the full potential of the genome, advance human health and the health of our planet. And that is why your vision and pursuit are at the very center of what our company does — our product design, our customer support model, our partnerships, and even our identity. We create the world’s most advanced sequencing systems to provide you the most complete and accurate view of genomes, transcriptomes, and epigenomes. Our founders invented a new way to study the synthesis and regulation of DNA, RNA, and proteins. Driven by a desire to advance human health, we’re harnessing advances in biochemistry, optics, nanofabrication, and more. We are passionate about developing products that empower scientists to explore the full spectrum of genetic variation in any organism — from unraveling the mystery of rare diseases to improving the world’s food supply. With world-class service and support, we keep your research progressing so you can focus on finding answers. We encourage you to see the whole picture — and consider us the partner you trust to see it too.

At PacBio, we’re devoted to empowering you. Pioneering the future through biology takes vision. You have to look beyond the status quo to what’s possible. We know your vision can reveal the full potential of the genome, advance human health and the health of our planet. And that is why your vision and pursuit are at the very center of what our company does — our product design, our customer support model, our partnerships, and even our identity. We create the world’s most advanced sequencing systems to provide you the most complete and accurate view of genomes, transcriptomes, and epigenomes. Our founders invented a new way to study the synthesis and regulation of DNA, RNA, and proteins. Driven by a desire to advance human health, we’re harnessing advances in biochemistry, optics, nanofabrication, and more. We are passionate about developing products that empower scientists to explore the full spectrum of genetic variation in any organism — from unraveling the mystery of rare diseases to improving the world’s food supply. With world-class service and support, we keep your research progressing so you can focus on finding answers. We encourage you to see the whole picture — and consider us the partner you trust to see it too.

PAVmed (NASDAQ: PAVM) is a highly-differentiated, multi-product medical device company employing a unique and proven business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This model enables us to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation.

For 85 years, PerkinElmer has pushed the boundaries of science in our food, industrial, life science and environmental markets. In addition to innovative laboratory technologies, our OneSource services division delivers a highly trained, experienced, and collaborative team of service engineers with solutions scalable and customizable to serve laboratory needs. We’ve always pursued science with a clear purpose – to help our customers achieve theirs. Our expert team brings technology and intangibles, like creativity, empathy, diligence, and a spirit of collaboration, in equal measure, to fulfill our customers’ desire to work better, innovate better, and create better. PerkinElmer is a leading, global provider of technology and service solutions that help customers measure, quantify, detect, and report in ways that help ensure the quality, safety, and satisfaction of their products. Science with Purpose. Learn more at www.perkinelmer.com.

Phalanx Biotech Group provides genomics research products and services worldwide to academic, pharmaceutical and biotech communities. We developed the OneArray® line of high-quality and affordable microarrays for expression profiling of whole genomes, microRNA, and custom targets. Our service specialists offer comprehensive services including sample preparation, expression analysis, and qPCR validation. In 2017, Phalanx is pleased to announce that it has added Next Generation Sequencing Services (NGS) and corresponding NGS Bioinformatics to its service offerings.

Disrupting research enzyme/protein production, we are the first to introduce a Taq Polymerase free from background DNA contamination. We are now proud to introduce our new RNA extraction free EF1 SARS-CoV-2 Detection Kit, CE marked for in vitro diagnostics! Find out how we plan to have the gold standard of testing available with results in less time it takes to explain your job to grandma!

As the leader in Decision Medicine™, Pillar’s technology platform drives significantly more efficient and accessible NGS testing with industry-leading accuracy and sensitivity. Pillar’s extensive portfolio applies across the entire patient journey, from profiling to therapy selection and monitoring, generating actionable insights to get patients on the right therapy faster In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly. For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%.

We sequence whole plasmids, amplicons, whole bacterial genomes, and colonies overnight, without the need for primers and minipreps. Plasmidsaurus is on a mission to accelerate new cures and promote a healthier planet by unlocking new levels of productivity in scientists using DNA tools to bring their ideas to life. The company’s DNA sequencing services are used daily by thousands of innovators, including Nobel prize winners, dynamic biotech startups, pharmaceutical companies, research labs, and DIY biohackers. Plasmidsaurus’s global network of labs operates day and night to enable world-changing discoveries.

Pleno Inc. is an early-stage San Diego startup company developing a multi-omic instrument platform to revolutionize biological target detection for clinical testing and biomedical research and enable a broad array of applications from screening and detection, to diagnostics, prognostics and beyond. We are driven and dedicated scientists, engineers and business professionals. We're developing an innovative and disruptive multi-omic instrument platform that's going to transform the insights from and application of biological information. We're in an exciting growth phase and are actively expanding our team. Join us to experience the energy and excitement of taking on the biggest challenges in biosciences and biotechnology to develop innovative solutions that will disrupt the industry. You'll have the support to flourish both professionally and personally, where your ideas are valued and your commitment and collaboration is key to our success.

Protein BioSolutions provides viable solutions for scientists involved in DNA sequencing and in protein production, purification, characterization and crystallography.

Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. We have developed an entirely novel, powerful and high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.

Psomagen, Inc., formerly Macrogen Corp, delivers genomic sequencing services to the clinical, academic, and consumer markets. Psomagen's labs are US-based and CLIA and CAP certified. Not only is the company accredited to perform the highest quality Sanger sequencing, Next-Generation Sequencing and Microarray Gene Analysis, it is also networked with Macrogen's worldwide headquarters, stretching its capabilities and capacity across a diverse set of labs around the world. Learn more at psomagen.com.

Quantapore Inc. is developing a nanopore based nucleic acid sequencing technology thatutilizes an optical read out which results in lower cost and higher throughput compared to electrical data acquisition.

QuickBiology is a fully automated, high-throughput genomic center equipped with all major next generation sequencing. QB provides state-of-the-art genomics technologies, comprehensive services, specialized expertise enabling these services in a cost-effective and timely manner to serve basic science and translational/clinical research. QB’s service included, but not limited to, RNA sequencing, whole exome sequencing, whole genome sequencing, ATAC sequencing and single cell RNA sequencing.

Our Somatic Genomics platform unveils a new universe of genetic variation to create transformational medicines. Learn more at Quotient-Tx.com

Cells are the basic unit of life. They power everything we do, and unlocking their secrets is the key to advancing our knowledge of every facet of biology, from development to disease. Our single cell, spatial, and in situ tools enable researchers to answer pressing questions about cells and their functional contributions to oncology, immunology, neuroscience, and much more—as evidenced by more than 5,500 publications citing our technology. We are dedicated to building the best products, delivering the best customer experience, and creating the best team to fuel new scientific discovery, no matter how challenging. And we won't stop until all of the cells' secrets are revealed.

RealSeq Biosciences’ core expertise includes innovative proprietary technologies for bias-free small RNA/miRNA NGS library construction, targeted NGS tools, and cf-RNA analysis (liquid biopsy) that form the basis of the Company’s life science research programs and product development.

Resolution Bioscience, a part of Agilent, is pioneering next generation cancer diagnostics that enable physicians to tailor treatments for each patient using only a blood test — a liquid biopsy. Our proprietary molecular analytics platform interrogates cell-free DNA for actionable information that, until now, has only been accessible through invasive biopsy procedures. We have developed over 50 focused panels and are currently working on companion diagnostics to support therapeutic approvals. We are dedicated to improving cancer outcomes through a suite of clinical tests to guide selection of targeted therapies and monitor their effectiveness over time.

Microfluidics for Molecular DiagnosticsCOVID-19: (12/2020) EUA for COVID-19™ MDx Assay

At Rondo Therapeutics we believe that our success as a company starts with building a culture based on teamwork, trust, career growth, and a sense of fun. If you are a fearless scientist driven to make new discoveries and you value collaboration, respect, and working in a team environment, then we want to hear from you! Join us in our mission to create novel molecules that bring new hope to cancer patients while advancing your career in a merit-based culture. Rondo Therapeutics is committed to advancing the field of immuno-oncology, with a focus on treating solid tumors that fail to respond to current therapies. Our solution is to create a new class of bispecific antibodies that safely engage the immune system to initiate and sustain a robust anti tumor response.

RTLGenomics is a full service sequencing company offering sequencing approaches including barcoding, metagenomicsand transcriptomics. A sister lab, MicroGen, is a CAP accredited clinical diagnostic laboratory.

Rutgers University is an academic institution that offers a wide range of undergraduate and graduate programs, conducts research, and provides educational services.

Sage Science products are built on the idea that science is more robust and reliable when it is based on high-precision, automated, reproducible technology instead of manually intensive steps that introduce variability and error. We look at molecular biology workflows and identify high-value steps that can be significantly improved with accurate, automated solutions. Our products not only reduce hands-on time and boost throughput, but they also improve data quality and downstream results for life science and diagnostic labs. The Sage Science portfolio includes products to perform DNA or cDNA size selection: Pippin Prep for short-read NGS platforms and the BluePippin for short and long-read NGS platforms. The SageELF provides whole-sample fractionation of DNA for various applications. The SageHLS offers a new twist on DNA target enrichment. DNA is first extracted from cells directly on the platform. Then Cas9 endonuclease/guide RNA complexes are used to excise and collect large targets (entire genes or genomic regions, up to 500MB in length) from a genome. Large target enrichment, called CATCH (Cas9 assisted targeting of chromosomal segments) is used to elucidate difficult genomic structures such as pseudogenes, SVs, and repeat elements. Sage Science is privately funded. It is headquartered and manufactures at 500 Cummings Center in Beverly, MA, USA.

Scisco Genetics Inc, a Seattle-based spin-off from the Fred Hutchinson Cancer Research Center, is a leading provider of sequencing services and products for genotyping the immune system.

SeqLL is a biotechnology company that specializes in Quantitative RNA & Specialty DNA Sequencing, offering True Single Molecule Sequencing technology.

seqWell was created to revolutionize NGS library prep to unlock the full potential of today’s DNA sequencing instruments. Our plexWell™ platform is a transformative library prep technology that allows for simple, scalable multiplexing of 100s to 1000s of samples without time- and cost-consuming normalization. plexWell has wide-ranging impact on applications from synthetic biology, targeted sequencing and single-cell analysis to low and high depth sequencing of human, plant, animal and microbial genomes. In addition to plexWell, seqWell is also developing library prep methods for reagent-based approaches for long-molecule phasing and read linking. We invite you to learn more at https://seqwell.com

SeraCare, part of LGC's Clinical Diagnostics Division, enables the promise of precision medicine by advancing the understanding of disease and providing assurance of the diagnostic result. Our innovative tools and technologies not only ensure the safe, effective, and accurate performance of diagnostic assays but also establish a framework for regulating, compiling, and interpreting data from precision diagnostics. Our portfolio includes a broad range of products such as quality control technologies, disease-state specimens and tissues for research and development, processed biological materials, and immunoassay reagents.

Serimmune is an immune intelligence company that provides a holistic view of immunity to identify environmental factors in disease and health. Serimmune’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity.

Singular Genomics is driving innovation at the forefront of multiomics. Dedicated to supporting the scientific community, we focus on creating scientific advancements influenced by real-world feedback and solution-oriented development. As a publicly-traded life science technology company, we specialize in advanced next-generation sequencing (NGS) and multiomic technologies, developing products that empower researchers and clinicians. The G4 Sequencing Platform, our first commercially available product, is an innovative benchtop sequencer featuring a novel 4-color rapid sequencing-by-synthesis (SBS) chemistry and advanced engineering, providing single-day turnaround times for various applications. Our recently launched G4X Spatial Sequencer, which is an upgrade to the G4 Sequencing Platform, is designed to offer high throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues. We are committed to unlocking the potential of our core technologies to reshape the future of multiomics. We offer a dynamic, fast-paced, results-oriented environment where employees can make a significant impact. Innovation, continuous learning, multi-disciplinary collaboration, and diversity of thought are pillars of our culture.

The Integrated Genomics Operation (IGO) at Memorial Sloan Kettering (MSK) is a collaborative core facility dedicated to generating high-quality genomics data for basic, translational, and clinical research projects. The core is focused on Illumina Next-Generation Sequencing (NGS) while also providing comprehensive genomics services including pathological review of tissue samples, fragment analysis, Sanger sequencing, and much more.

info@smlgenetree.com | www.smlgenetree.com | SML Genetree is recognized as a premier partner in developing technology and on-time delivery, providing both basic research of molecular biology and applied research in molecular diagnosis. SML Genetree is an affiliate of Samkwang Medical Laboratories (SML), one of the largest diagnostic commercial labs in South Korea in 1985.

Antibody Libraries are the sources from which therapeutic antibodies can be generated using phage or yeast display. Specifica’s Generation 3 platform generates drug like antibodies, with broad diversity, high affinities and few biophysical liabilities, directly from naïve libraries. In addition to in-house designs, Specifica also collaborates closely with partners to create custom libraries in which essential elements are optimized according to partner needs.

Speed BioSystems is a biomedical research reagents company that offers high-quality products with speedy delivery services.

Stony Brook Medicine expresses our shared mission of research, clinical care and education – a mission embraced by our faculty, staff, researchers, and students. It is the embodiment of everything we do on behalf of the health of patients – not only here in our community, but also in the region and worldwide. Stony Brook Medicine comprises five Health Sciences schools — Renaissance School of Medicine, School of Dental Medicine, School of Health Technology and Management, School of Nursing and School of Social Welfare — as well as Stony Brook University Hospital, Stony Brook Southampton Hospital, Stony Brook Eastern Long Island Hospital, Stony Brook Children’s Hospital and more than 200 community-based healthcare settings throughout Suffolk County. Our health sciences schools work in tandem with our research and clinical care teams to deliver the best ideas in medicine to patients. As an academic medical center, we are all about ideas. Creating them. Nurturing them. Protecting them. Challenging them. Improving them. Teaching them to others. And most importantly of all, delivering them to patients and their families – sooner, smarter and better. An “idea” can be a new treatment protocol, best practices, a bright new researcher we’ve brought in from another institution, the convenience of an outpatient clinic, or simply a more user-friendly way to access our medical care. Ideas drive us, they thrive here, and we are committed to bringing more of them to our patients than anyone else.

Strata Oncology is a high-growth, state-of-the art, precision oncology company, delivering a new standard of care that integrates molecular profiling, decision support and clinical trial participation into routine practice. We do this by partnering with major healthcare systems across the country, who systematically send their cancer patients’ biopsies to our high-throughput CLIA lab for genomic sequencing, with results provided to the oncologist within days, indicating the tumor profile, and matches to appropriate therapies and drug trials. This accelerates the move to personalized medicine – right medicines to the right patients at the right time. Our personnel are passionate about and committed to making a positive difference, now, in the lives of cancer patients and their families. Clinicians, pathologists, bioinformaticists, software engineers, lab technicians and more, coming together to give access to those without, uncovering insight that might be hidden, all while spreading urgency to all. Experience a career that connects a fast-paced team environment with a worthy pursuit – feel good about what you’ve accomplished at the end of every day!

Syd Labs, a recombinant company based in Boston, Massachusetts, is dedicated to providing quality products and services for research and development in academy, industry, and government. We have always tried our best to let you, our valuable customers and partners, save money and work better. Syd Labs, Inc provides very comprehensive and competitive services for antibody services, from peptide synthesis, gene synthesis, protein expression, rabbit and mouse polyclonal antibody development, mouse, rat, and rabbit monoclonal antibody development, cloning variable regions of hybridoma cell lines, antibody humanization and engineering, stable cell line generation, ELISA assay development, and so on. The lowest prices are guaranteed. If you find any US company providing the same quality services with lower prices, we will return the difference to you.

Synbio Technologies aims to become the most trusted provider of DNA solutions that empower scientific discoveries by providing highly-accurate and cost-effective synthetic biology services and products for researchers around the world. We have developed a full range of DNA reading (sequencing), DNA writing (synthesis), and DNA editing (engineering) capabilities for various applications, including diagnostic DNA probes, precision medicine, protein production, antibody discovery, vaccine development, novel enzymes, molecular breeding, biofuel implication, and more. Our scientific capabilities cover all facets of DNA synthesis and engineering, offering a full range of support for molecular biology work, including but not limited to, oligo synthesis, gene synthesis, subcloning & PCR cloning, plasmid preparation, mutagenesis, DNA variant libraries, CRISPR sgRNA, protein expression and purification in multiple systems. Relying on our strong DNA sequencing, synthesis, engineering technology platform, and expertise in bioinformatics analysis, we have developed proprietary algorithms to facilitate and expedite the antibody discovery process. Our antibody discovery services include hybridoma sequencing, immune repertoire sequencing, antibody design and production, AI-guided heavy chain and light chain pairing, antibody humanization, affinity maturation, and sdAb.

Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a Takara Bio company, develops, manufactures, and distributes a wide range of life science reagents under the Takara®, Cellartis®, and Clontech® brands. Our products support applications including stem cell research; NGS; gene discovery, regulation, and function studies; protein expression and purification; RNAi and gene editing; and plant and food research.

Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.

Tesis Biosciences’ unique integrated medical platform is revolutionizing targeted genetic sequencing. Precision-based medicine to help treat major chronic diseases. Our mission is to change medicine by providing physicians, hospitals, and researchers with the tools to help patients treat and overcome major chronic conditions such as heart and lung disease, cancer, diabetes, and Alzheimer’s through advanced genetic testing. Through our collaborative efforts utilizing our unique processes, we help medical device and pharmaceutical companies bring to market products that improve the quality of life for patients.

At Theragen, we strive to improve patient care and surgical fusion outcomes via non-invasive therapeutic electrical stimulation, advanced patient insights, and exceptional customer service. Theragen recently launched ActaStim-S, the smallest, most digitally capable, and data-driven non-invasive bone growth stimulator in over 2-decades. ActaStim-S assumed first-mover status by combining all-day wearability, proven capacitive coupling therapy, and automated daily clinical data capture to engage patients, enable compliance, and generate insight reports to inform clinicians when patients need guidance to stay on their healing journey.

Thermagenix supplies high-quality reagents that measurably improve PCR fidelity and performance.

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Trace Genomics is a pioneer in the use of hi-definition genomics to activate the hidden insights in soil for healthier soils and a healthier planet. Through innovation in genomics, soil science and machine learning, Trace Genomics creates a pathway to deliver targeted database insights and actions at cost-speed-scale-accuracy for partners who are advancing modern farming solutions for a net-zero food production system. Where most companies deliver a partial picture, we provide a comprehensive and precise understanding of the soil’s composition—analyzing the soil’s biology, physical properties and chemistry. Trace Genomics has won several awards, including being selected as a 2020 Technology Pioneer by the World Economic Forum, Winner of FoodShot Global’s Innovating Soil 3.0 Challenge, Forbes Top 25 Most Innovative AgTech, THRIVE Top 50 AgTech, 2022 Global Cleantech top 100 start-ups and many more.

At TRACER we are specialized in first-in-human studies with the use of nuclear and optical molecular imaging techniques. By labeling an antibody, small molecule, peptide, nanoparticle, protein, or any other compound of interest with a fluorescent dye or a radionuclide, fast in human data can be obtained with an indication of the potential efficacy of the novel drug, even before the classical phase 1-3 clinical trials. This can lead to a more efficient and less costly drug development process. We assist our sponsors in the labeling of their lead compounds and execute first-in-human studies to visualize and quantify the biodistribution and pharmacokinetics of the compound. With this information a “ go/no-go” decision can be made before the compound proceeds to the next phase in clinical development where costs are larger and time is valuable. Early in-human studies are approved by the EMA and FDA through the so-called principle of microdosing. It allows you to often skip (large) animal models and go straight into the patient population.

TrimGen is a precision medicine company that specializes in pharmacogenomics for behavioral health and chronic pain.

The Tufts facility works to provide quick and convenient, high quality services to scientists from academia and industry around the world. Although the primary mission is support of the researchers at Tufts University, many of its users are from outside of Tufts. They provide the following services:DNA SynthesisDNA SequencingNext-gen SequencingPeptide SynthesisProtein SequencingMass Spectrometer Analysis

Twist Bioscience is a synthetic biology company based in South San Francisco, California. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA. Twist Bioscience serves Life Science researchers who are changing the world for the better. Coming from diverse fields of medicine, agriculture, industrial chemicals and data storage, scientists use our synthetic genes, oligo pools, and NGS target enrichment to better lives and improve the sustainability of the planet. Twist Bioscience is uniquely positioned to help accelerate these efforts by providing precision at a scale that is otherwise unavailable. Our technology overcomes inefficiencies and enables cost-effective, rapid, precise, high-throughput DNA synthesis and sequencing. We offer both the quality and quantity researchers need now to rapidly realize opportunities ahead. Twitter @TwistBioscience Facebook facebook.com/TwistBioscience YouTube youtube.com/TwistBioscience #WeMakeDNA

Universal Sequencing Technology focuses on innovative Long-Read DNA Sequencing solutions. Our Tell-Seq technology simply turns a 2nd generation DNA sequencer into a 3rd gen, Long-Read Sequencer. The affordable TELL-Seq WGS library prep kit is used in Metagenomics, de novo Assembly, Whole Genome Phasing, and Structural Variant identification. We provide the kit and the analysis pipeline and all you need are the samples and some common lab equipment. No need to buy expensive 3rd generation sequencers. No need to buy droplet making equipment. No need to follow overly complicated protocols. No longer limited by genome size. The Tell-Seq WGS Library Prep kit is affordable without the added expense of an instrument. The protocol takes only 3 hours to run and can be used for genomes ranging from 1 Mb to 5 Gb. Again, this is Long-Read Sequencing Made Simple.

Variant Bio is developing therapies that will improve global health by studying the genes of people who are outliers for medically relevant traits. They’re using cutting-edge sequencing technology, statistical genetics, and machine learning to identify entirely new therapeutic targets.

Varigen Biosciences Corporation is using metagenomics tools to investigatemicrobial diversity and develop natural products.

Velsera connects healthcare and life sciences to reveal the true promise of precision medicine — a continuous flow of knowledge between researchers, scientists, and clinicians around the world, fueling innovation and creating insights that radically improve human health. Our goal is to use data to radically improve healthcare globally and create value through multiomics and insights. If you’re interested in learning more about Velsera, please follow us and visit our website at velsera.com! Looking for someone to get in touch with? Please email hello@velsera.com

At Veritas, we apply science and our global resources to bring genetic and genomic diagnostics to people to extend and significantly improve their lives. Our global portfolio includes preventive medicine, perinatal medicine, and genomic diagnostic services. In March 2022 Veritas announced that it was becoming part of LetsGetChecked, a global healthcare solutions company based in Dublin and New York. In keeping with our responsibility as a leading biotechnology company, we collaborate with healthcare providers, governments, and local communities to support and expand access to genetic and genomic medicine reliably and affordably around the world.

Verogen is a California-based company that develops and distributes next-generation gene sequencing panels and genetic code analyzing products for the healthcare sector.

Volta Labs is a genomics applications company that has developed a cutting-edge digital fluidics platform to maximize performance and scalability of sample preparation in genomics while providing unparalleled consistency. Volta is transforming the way biological research and analyses are performed, allowing scientists to focus on what they do best -- pushing the boundaries of biology. As a collective of scientists and builders working at the intersection of engineering and biology, we imagine a world where extracting vital information from biological samples is as simple as pressing a button. That's our vision, and we're turning it into reality. Our HQ is in Boston’s Seaport, where we develop and manufacture our technology. We believe in cross-functional collaboration and continuous learning – whether your interest is in biology, MechEng, CompEng, or simply joining a fast-growing startup striving to make the world a better place, we'd love to welcome you to our team. Check out some of our blog posts to learn more about work life at Volta.

Genomics Core Facility at West Virginia University is not-for-profit service facility open to all. The facility offers Next Generation Sequencing, Sanger Sequencing, Microarrays services.

At the Wyss Institute, we leverage recent insights into how Nature builds, controls and manufactures to develop new engineering innovations - a new field of research we call Biologically Inspired Engineering. Our scientists, engineers and clinicians, who come from Harvard's Schools of Medicine, Engineering, Arts & Sciences, Design, and Education as well as 12 collaborating academic institutions and hospitals, work alongside staff with industrial experience in product development to engineer transformative solutions to some of the world’s greatest problems. By emulating biological principles of self assembly, organization and regulation, we are developing disruptive technology solutions for healthcare, energy, architecture, robotics, and manufacturing, which are translated into commercial products and therapies through formation of new startups and corporate alliances.

xMD Diagnostics, Inc. is a molecular diagnostics tools company focused on developing a line of laboratory instruments and consumables for the rapidly growing research, biopharmaceutical and commercial clinical laboratory (CLIA) precision diagnostics markets. xMD's goal is to significantly improve pathologists', oncologists' and other physicians' ability to diagnose, monitor and treat patients with cancer and other serious genetic diseases.

For more than 300 years, Yale University has inspired the minds that inspire the world. Based in New Haven, Connecticut, Yale brings people and ideas together for positive impact around the globe. A research university that focuses on students and encourages learning as an essential way of life, Yale is a place for connection, creativity, and innovation among cultures and across disciplines.

Zafrens is a therapeutics company pioneering an ultra-high throughput platform to isolate, culture, image, and sequence millions of cells per day. The proprietary platform allows for full characterization of diverse cell populations, as well as directly correlating molecular profiles (DNA, RNA, protein) to cell phenotype and function. The company’s mission is to unlock the full story of every cell to accelerate drug discovery.

Since its inception in 1994, Zymo Research has been proudly serving the scientific community by providing innovative, reliable, and high quality research tools at affordable prices. Our vision..."The Beauty of Science is to Make Things Simple"​ is now truer than ever. Whether it's epigenetics, DNA, RNA, E. coli, or yeast based research, our philosophy remains the same: To provide the highest quality products in the industry while ensuring they are both simple to use and reliable in their performance. Zymo Research is historically recognized for its innovation of high quality nucleic acid purification technologies. Under the branding DNA Purification Made Simple™ and RNA Purification Made Simple™, our technologies are pushing the limits of what is possible with nucleic acid isolation. As The Epigenetics Company™, Zymo Research has also received much attention for its rapidly expanding portfolio of epigenetics products and services. It is our objective to develop and provide the most comprehensive set of tools for DNA, RNA, and epigenetic research and analysis available today. Thousands of peer-reviewed scientific publications from researchers around the world feature our technologies. Through innovation, our scientists have made streamlined DNA methylation detection possible, pioneered the micro-elution column for DNA and RNA purification, developed the simplest and the most sophisticated methods for high-quality plasmid DNA purification, and patented the first RNA purification directly from Trizol without phase separation among many other leading technologies in the industry. At Zymo Research, we are committed to quality and guarantee that all of our products and service will meet and exceed your expectations. We pledge to be honest and responsible for everything we do with you. We will treat you as we would like to be treated. Together, we will build a brighter future.